Holen Sie sich die Stockscreener-App
10.30
0.08%
0.0085
Schlusskurs vom Vortag:
$10.30
Offen:
$10.3
24-Stunden-Volumen:
255.87K
Relative Volume:
3.20
Marktkapitalisierung:
$324.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.29%
1M Leistung:
+0.83%
6M Leistung:
+2.84%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.29
$10.30
1-Wochen-Bereich:
$10.27
$10.30
52-Wochen-Spanne:
$9.97
$11.20
Voyager Acquisition Corp Stock (VACH) Company Profile
Firmenname
Voyager Acquisition Corp
Sektor
Branche
Telefon
03477204333
Adresse
C/O WINSTON & STRAWN LLP, HOUSTON
Vergleichen Sie VACH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VACH
Voyager Acquisition Corp
|
10.29 | 324.47M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
6.79 | 2.09B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.27 | 696.54M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.72 | 461.01M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.31 | 453.59M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.22 | 453.53M | 0 | 0 | 0 | 0.00 |
Voyager Acquisition Corp Aktie (VACH) Neueste Nachrichten
Veraxa Biotech, OmniAb collaborate on bispecific ADC programme - World Pharmaceutical Frontiers
European de-SPAC M&A soars back — Dealspeak EMEA - ION Analytics
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - GlobeNewswire Inc.
1,100,000 Shares in Voyager Acquisition Corp. (NASDAQ:VACH) Purchased by Aristeia Capital L.L.C. - MarketBeat
1,518,939 Shares in Voyager Acquisition Corp. (NASDAQ:VACH) Purchased by AQR Arbitrage LLC - MarketBeat
Berkley W R Corp Purchases New Shares in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - The Manila Times
Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal - MSN
Whitebox Advisors LLC Invests $1.50 Million in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
Shaolin Capital Management LLC Buys New Position in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
Veraxa to go public in $1.6bn SPAC deal with Voyager - MSN
Heights Capital Management Inc. Takes Position in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
Duane Morris Represents Veraxa in $1.3 Billion SPAC Merger Agreement - Duane Morris LLP
Veraxa Biotech to go public via $1.64bn SPAC deal with Voyager Acquisition - World Pharmaceutical Frontiers
Switzerland: Voyager Acquisition Corp combines with Veraxa for Nasdaq IPO - Investors in Healthcare
One of the largest preclinical ADC deals: Taiho Pharma’s US$1.14bn acquisition of Araris Biotech - Investors in Healthcare
Sweden: Biotage recommends shareholders accept KKR’s SEK11.607bn public takeover offer - Investors in Healthcare
New Providence Acquisition Corp. III (NPACU) Prices $261M IPO - SPAC Insider
Voyager Acquisition Corp Inc. (VACH) Price Performance: The Role of Supply and Demand - investchronicle.com
Roku Inc (ROKU) Stock: From Low to High in 52 Weeks - investchronicle.com
Veraxa through a SPAC heads to Nasdaq - BioWorld MedTech
Astera Labs Inc (ALAB) Stock: A Year of Stock Market Dynamics - investchronicle.com
German antibody maker valued at $1.6B in blank-check merger - BioPharma Dive
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
Cancer drug developer Veraxa to list in US via $1.64B SPAC merger - FirstWord Pharma
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Actinium Pharmaceuticals Inc (ATNM Stock: A Sea of Opportunity - investchronicle.com
Dynex Capital, Inc (DX) Stock: Navigating a Year of Volatility - investchronicle.com
Swiss Drug Developer Veraxa To List In US In $1.6B SPAC Deal - Law360
Veraxa to list on Nasdaq through Voyager Acquisition Corp merger - The Pharma Letter
Antero Resources Corp (AR) Stock: From Low to High in 52 Weeks - investchronicle.com
Vistra Corp (VST) Stock: Navigating a Year of Stock Volatility - investchronicle.com
HST’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
IPO Radar: VERAXA, CATL and Zopa - The Armchair Trader
German cancer antibody biotech eyes SPAC as route to Nasdaq - Fierce Biotech
Voyager Acquisition, VERAXA Biotech to Merge, Creating $1.64 Billion Public Cancer Therapy Company - marketscreener.com
Xlife Sciences’ VERAXA Biotech to Merge with Voyager Acquisition Corp. - TipRanks
ForexTV | Small Business Resources - ForexTV
Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook - The Manila Times
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination to Advance Next-Generation Cancer Therapies - Nasdaq
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies - TradingView
Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp. - marketscreener.com
Voyager Acquisition (NASDAQ:VACH) Trading Down 0.2%Here's Why - MarketBeat
Ireland: Investindustrial agrees acquisition of DCC’s healthcare division for £1.05bn - Investors in Healthcare
Voyager Acquisition (NASDAQ:VACH) Trading Down 0.2% – Time to Sell? - Defense World
Americas Technology Acquisition (NYSEARCA:ATA) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Spark I Acquisition (NASDAQ:SPKL) Stock Price Down 0.3% – Time to Sell? - Defense World
Lumina Gold Corp. (OTCMKTS:LMGDF) Short Interest Update - Defense World
AudioEye, Inc. (NASDAQ:AEYE) Receives Average Rating of “Buy” from Brokerages - Defense World
France: Mérieux Equity Partners sells stake in Theravia to Norgine - Investors in Healthcare
UK: Apposite Capital’s HCML acquires ILS - Investors in Healthcare
Finanzdaten der Voyager Acquisition Corp-Aktie (VACH)
Es liegen keine Finanzdaten für Voyager Acquisition Corp (VACH) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
16.89%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):